Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dolby Laboratories earns most of its revenue from licensing breakthrough formats like Dolby Atmos and Dolby Vision, so every footnote in a 10-K or 10-Q matters. Royalty rates, unit shipments, and new patent wins are buried deep in the text—making DLB filings uniquely data-dense for a company with minimal physical inventory.
Stock Titan’s AI engine dissects each document the moment it hits EDGAR. Whether you need a Dolby Laboratories quarterly earnings report 10-Q filing to gauge device penetration, or want Dolby Laboratories insider trading Form 4 transactions in real time, our platform translates legalese into clear language and trend charts. The same AI model answers natural questions such as “understanding Dolby Laboratories SEC documents with AI” or “Dolby Laboratories 8-K material events explained,” so you never waste time hunting for a single note about deferred revenue.
- 10-K & 10-Q: Royalty streams, segment margins, R&D spend—see the Dolby Laboratories annual report 10-K simplified with key tables extracted.
- Form 4: Track Dolby Laboratories executive stock transactions Form 4 alongside price charts for context.
- 8-K & press releases: Immediate alerts when new license deals or litigation updates drop.
- Proxy (DEF 14A): Dig into Dolby Laboratories proxy statement executive compensation to see how bonuses tie to royalty growth.
Analysts use these insights to compare quarter-over-quarter royalty trends, monitor patent litigation disclosures, and spot insider sentiment shifts. From “Dolby Laboratories Form 4 insider transactions real-time” to “Dolby Laboratories earnings report filing analysis,” every document is parsed, summarized, and linked—saving hours and sharpening decisions.
Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of
On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of
Dolby Laboratories insider plans Rule 144 share sale. A holder has filed a notice to sell 4,500 shares of common stock of Dolby Laboratories under Rule 144. The proposed sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $304,035.75 based on the filing information. The shares were acquired on 12/01/2025 via a stock option exercise from the issuer for cash, and the same number of shares is slated for sale. The filing notes that 60,845,846 shares of the issuer’s common stock were outstanding, providing context for the size of this planned transaction.
Dolby Laboratories, Inc. (DLB) President and CEO Kevin Yeaman, who is also a director, reported multiple transactions in Class A common stock and related stock options. On November 24, 2025, a family trust exercised employee stock options for 25,000 shares at $45.50 and 11,699 shares at $64.60, increasing indirect holdings. That same day, the trust sold 36,699 shares at a weighted average price of $66.9066, with the shares sold in multiple transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.
On November 26, 2025, Mr. Yeaman gifted 16,348 shares of Class A common stock from the trust to a donor-advised fund for charitable purposes. Following the reported transactions, indirect holdings include 98,377 shares in the family trust and additional indirect ownership through restricted stock units and shares held by a son.
Dolby Laboratories, Inc. (DLB)11/25/2025, a director sold 3,300 shares of Class A common stock in an open market transaction coded "S" at a price of $67.85 per share. After this sale, the director beneficially owned 9,107 shares of Class A common stock.
This remaining amount includes 3,140 shares underlying restricted stock units that are subject to forfeiture until they vest, meaning the director must meet vesting conditions before fully owning those shares.
Dolby Laboratories (DLB) has a planned sale of restricted common stock under Rule 144. The notice covers the proposed sale of 3,300 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $223,905.00. The issuer has 60,845,846 shares of common stock outstanding.
The seller acquired these shares as restricted stock directly from the issuer in two grants: 2,783 shares on 02/06/2023 and 517 shares on 02/05/2024, both noted as not involving special payment arrangements. The approximate date of sale listed in the notice is 11/25/2025.
Dolby Laboratories, Inc. insider activity: A company officer, identified as SVP of the Advanced Technology Group, reported selling 3,000 shares of Dolby Laboratories Class A common stock on 11/21/2025 at a price of $65.55 per share. After this transaction, the reporting person beneficially owns 67,435 shares of Class A common stock.
The remaining holdings include 47,766 shares underlying restricted stock units that may be forfeited if they do not vest, meaning a substantial portion of the reported ownership is still subject to vesting conditions over time.
Dolby Laboratories (DLB)11/20/2025, the executive sold 6,164 shares of Dolby Class A common stock at a price of $66.12 per share. After this transaction, the executive beneficially owns 115,338 shares of Class A common stock. This total includes 48,526 shares underlying restricted stock units that may be forfeited if they do not vest, as well as 284 shares and 67 shares acquired through the company’s Employee Stock Purchase Plan on May 15, 2025 and November 17, 2025.
Dolby Laboratories (DLB) has a Form 144 notice indicating a planned sale of 36,699 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of
The shares to be sold were acquired on 11/24/2025 via a stock option exercise from the issuer, paid in cash, on the same date. Over the past three months, the Yeaman Family Trust sold 25,000 common shares on 10/14/2025 for gross proceeds of
An insider of DLB has filed a Form 144 indicating an intent to sell up to 3,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of
Dolby Laboratories (DLB) filed a Form 144 indicating a planned sale of restricted stock. The notice covers the proposed sale of 6,164 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $407,563.68. The filing notes that 60,845,846 shares of the issuer’s common stock are outstanding.
The shares to be sold were originally acquired as restricted stock from the issuer in multiple grants between 2013 and 2021, including blocks of 2,356 shares on 12/15/2020 and 1,627 shares on 12/16/2021, all listed as fully paid in cash or not requiring additional consideration. The person on whose behalf the sale is planned represents that they are not aware of any undisclosed material adverse information about the company’s operations.
FAQ
What is the current stock price of Dolby Laboratories (DLB)?
What is the market cap of Dolby Laboratories (DLB)?
